Advertisement

Human Papillomavirus (HPV)

  • Amelia B. ThompsonEmail author
  • Lisa C. Flowers
Chapter
  • 44 Downloads

Abstract

Human papillomavirus (HPV) is a double stranded DNA (dsDNA) virus that often causes an asymptomatic infection and clears spontaneously. However, HPV infection may result in genital warts, dysplasia, and squamous cell carcinoma of the head, neck and genitalia. Genital HPV is the most common sexually transmitted infection (STI) in the United States. HPV infection may lead to significant morbidity for both immunocompetent and immunocompromised persons. Immunocompromised persons, including those with human immunodeficiency virus (HIV) infection, are more likely to develop persistent HPV infection and its associated complications. All adolescents and young adults should get the HPV vaccine, ideally prior to initiation of sexual intercourse, in order to prevent infection and the subsequent potential for progression to malignancy.

Keywords

Human papillomavirus Genital warts Recurrent respiratory papillomatosis Dysplasia Cancer 

References

  1. 1.
    Centers for Disease Control and Prevention. CDC Fact Sheet: incidence, prevalence, and cost of sexually transmitted infections in the United States. 2013. p. 1–4. Available from: https://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf.
  2. 2.
    Hernandez BY, Wilkens LR, Zhu X, Thompson P, McDuffie K, Shvetsov YB, et al. Transmission of human papillomavirus in heterosexual couples. Emerg Infect Dis. 2008;14(6):888–94.PubMedPubMedCentralGoogle Scholar
  3. 3.
    Hutter JN, Decker CF. Human papillomavirus infection. Dis Mon. 2016;62(8):294–300.PubMedGoogle Scholar
  4. 4.
    Anderson TA, Schick V, Herbenick D, Dodge B, Fortenberry JD. A study of human papillomavirus on vaginally inserted sex toys, before and after cleaning, among women who have sex with women and men. Sex Transm Infect. 2014;90(7):529–31.PubMedGoogle Scholar
  5. 5.
    Ryndock EJ, Meyers C. A risk for non-sexual transmission of human papillomavirus? Expert Rev Anti Infect Ther. 2014;12(10):1165–70.PubMedGoogle Scholar
  6. 6.
    Wiley D, Masongsong E. Human papillomavirus: the burden of infection. Obstet Gynecol Surv. 2006;61(6 Suppl 1):S3–14.PubMedGoogle Scholar
  7. 7.
    Widdice L, Ma Y, Jonte J, Farhat S, Breland D, Shiboski S, et al. Concordance and transmission of human papillomavirus within heterosexual couples observed over short intervals. J Infect Dis. 2013;207(8):1286–94.PubMedPubMedCentralGoogle Scholar
  8. 8.
    Workowski KA. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S759–62.PubMedGoogle Scholar
  9. 9.
    Chesson HW, Dunne EF, Hariri S, Markowitz LE. The estimated lifetime probability of acquiring human papillomavirus in the United States. Sex Transm Dis. 2014;41(11):660–4.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Molano M, Van den Brule A, Plummer M, Weiderpass E, Posso H, Arslan A, et al. Determinants of clearance of human papillomavirus infections in Colombian women with normal cytology: a population-based, 5-year follow-up study. Am J Epidemiol. 2003;158(5):486–94.PubMedGoogle Scholar
  11. 11.
    Bonanni P, Bechini A, Donato R, Capei R, Sacco C, Levi M, et al. Human papilloma virus vaccination: impact and recommendations across the world. Ther Adv Vaccines. 2015;3(1):3–12.PubMedPubMedCentralGoogle Scholar
  12. 12.
    de Martel C, Ferlay J, Franceschi S, Vignat J, Bray F, Forman D, et al. Global burden of cancers attributable to infections in 2008: a review and synthetic analysis. Lancet Oncol. 2012;13(6):607–15.PubMedGoogle Scholar
  13. 13.
    Markowitz LE, Liu G, Hariri S, Steinau M, Dunne EF, Unger ER. Prevalence of HPV after introduction of the vaccination program in the United States. Pediatrics. 2016;137(3):1–9.Google Scholar
  14. 14.
    Hofstetter AM, Ompad DC, Stockwell MS, Rosenthal SL, Soren K. Human papillomavirus vaccination and cervical cytology outcomes among urban low-income minority females. JAMA Pediatr. 2016;170(5):445–52.PubMedGoogle Scholar
  15. 15.
    Bansal A, Singh MP, Rai B. Human papillomavirus-associated cancers: a growing global problem. Int J Appl Basic Med Res. 2016;6(2):84–9.PubMedPubMedCentralGoogle Scholar
  16. 16.
    de Villiers EM. Cross-roads in the classification of papillomaviruses. Virology. 2013;445(1–2):2–10.PubMedGoogle Scholar
  17. 17.
    Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, et al. A review of human carcinogens--part B: biological agents. Lancet Oncol. 2009;10(4):321–2.PubMedGoogle Scholar
  18. 18.
    Whiteside MA, Siegel EM, Unger ER. Human papillomavirus and molecular considerations for cancer risk. Cancer. 2008;113(10 Suppl):2981–94.PubMedGoogle Scholar
  19. 19.
    Nguyen HP, Ramirez-Fort MK, Rady PL. The biology of human papillomaviruses. Curr Probl Dermatol. 2014;45:19–32.PubMedGoogle Scholar
  20. 20.
    Graham SV. Human papillomavirus: gene expression, regulation and prospects for novel diagnostic methods and antiviral therapies. Future Microbiol. 2010;5(10):1493–506.PubMedPubMedCentralGoogle Scholar
  21. 21.
    Joyce JG, Tung JS, Przysiecki CT, Cook JC, Lehman ED, Sands JA, et al. The L1 major capsid protein of human papillomavirus type 11 recombinant virus-like particles interacts with heparin and cell-surface glycosaminoglycans on human keratinocytes. J Biol Chem. 1999;274(9):5810–22.PubMedGoogle Scholar
  22. 22.
    Evander M, Frazer IH, Payne E, Qi YM, Hengst K, McMillan NA. Identification of the alpha6 integrin as a candidate receptor for papillomaviruses. J Virol. 1997;71(3):2449–56.PubMedPubMedCentralGoogle Scholar
  23. 23.
    Doorbar J, Egawa N, Griffin H, Kranjec C, Murakami I. Human papillomavirus molecular biology and disease association. Rev Med Virol. 2015;25(Suppl 1):2–23.PubMedPubMedCentralGoogle Scholar
  24. 24.
    Maglennon GA, Doorbar J. The biology of papillomavirus latency. Open Virol J. 2012;6:190–7.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Melsheimer P, et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res. 2008;68(1):307–13.PubMedGoogle Scholar
  26. 26.
    Lechner MS, Laimins LA. Inhibition of p53 DNA binding by human papillomavirus E6 proteins. J Virol. 1994;68(7):4262–73.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Li TT, Zhao LN, Liu ZG, Han Y, Fan DM. Regulation of apoptosis by the papillomavirus E6 oncogene. World J Gastroenterol. 2005;11(7):931–7.PubMedPubMedCentralGoogle Scholar
  28. 28.
    Longworth MS, Laimins LA. Pathogenesis of human papillomaviruses in differentiating epithelia. Microbiol Mol Biol Rev. 2004;68(2):362–72.PubMedPubMedCentralGoogle Scholar
  29. 29.
    Wallace NA, Galloway DA. Novel functions of the human papillomavirus E6 Oncoproteins. Annu Rev Virol. 2015;2(1):403–23.PubMedGoogle Scholar
  30. 30.
    Andersson S, Hellstrom AC, Ren ZP, Wilander E. The carcinogenic role of oncogenic HPV and p53 gene mutation in cervical adenocarcinomas. Med Oncol. 2006;23(1):113–9.PubMedGoogle Scholar
  31. 31.
    Gormley RH, Kovarik CL. Dermatologic manifestations of HPV in HIV-infected individuals. Curr HIV/AIDS Rep. 2009;6(3):130–8.PubMedGoogle Scholar
  32. 32.
    Ahmed AM, Madkan V, Tyring SK. Human papillomaviruses and genital disease. Dermatol Clin. 2006;24(2):157–65, viPubMedGoogle Scholar
  33. 33.
    Virgilio E, Balducci G, Mercantini P, Tozzi F, Ziparo V, Ferri M. Perianal giant condyloma acuminatum of Buschke-Loewenstein: a carcinoma-like condyloma or a condyloma-like carcinoma? ANZ J Surg. 2015;85(5):394–5.PubMedGoogle Scholar
  34. 34.
    Garland SM, Steben M, Sings HL, James M, Lu S, Railkar R, et al. Natural history of genital warts: analysis of the placebo arm of 2 randomized phase III trials of a quadrivalent human papillomavirus (types 6, 11, 16, and 18) vaccine. J Infect Dis. 2009;199(6):805–14.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Carifi M, Napolitano D, Morandi M, Dall'Olio D. Recurrent respiratory papillomatosis: current and future perspectives. Ther Clin Risk Manag. 2015;11:731–8.PubMedPubMedCentralGoogle Scholar
  36. 36.
    Hermann JS, Weckx LY, Monteiro Nurmberger J, Santos Junior GF, Campos Pignatari AC, Nagata Pignatari SS. Effectiveness of the human papillomavirus (types 6, 11, 16, and 18) vaccine in the treatment of children with recurrent respiratory papillomatosis. Int J Pediatr Otorhinolaryngol. 2016;83:94–8.PubMedGoogle Scholar
  37. 37.
    Derkay CS. Task force on recurrent respiratory papillomas. A preliminary report. Arch Otolaryngol Head Neck Surg. 1995;121(12):1386–91.PubMedGoogle Scholar
  38. 38.
    Derkay CS, Wiatrak B. Recurrent respiratory papillomatosis: a review. Laryngoscope. 2008;118(7):1236–47.PubMedGoogle Scholar
  39. 39.
    Mallen-St Clair J, Alani M, Wang MB, Srivastan ES. Human papillomavirus in oropharyngeal cancer: the changing face of a disease. Biochim Biophys Acta. 2016;1866(2):141–50.PubMedGoogle Scholar
  40. 40.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917.PubMedGoogle Scholar
  41. 41.
    Oriel JD. Natural history of genital warts. Br J Vener Dis. 1971;47(1):1–13.PubMedPubMedCentralGoogle Scholar
  42. 42.
    Watson RA. Human papillomavirus: confronting the epidemic-a Urologist's perspective. Rev Urol. 2005;7(3):135–44.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee SK, Kuypers JM, et al. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731–8.PubMedGoogle Scholar
  44. 44.
    Massad LS, Xie X, Darragh T, Minkoff H, Levine AM, Watts DH, et al. Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol. 2011;118(4):831–9.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2017: a review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2017;67(2):100–21.PubMedGoogle Scholar
  46. 46.
    Saslow D, Solomon D, Lawson HW, Killackey M, Kulasingam SL, Cain J, et al. American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Am J Clin Pathol. 2012;137(4):516–42.PubMedGoogle Scholar
  47. 47.
    US Department of Health and Human Services: AIDS Info. Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Exposed and HIV-Infected Children: Department of Health and Human Services. Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/oi_guidelines_pediatrics.pdf
  48. 48.
    Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR, Luff RD, et al. The lower Anogenital squamous terminology standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol. 2013;32(1):76–115.Google Scholar
  49. 49.
    Nayar R, Wilbur DC. The pap test and Bethesda 2014. “The reports of my demise have been greatly exaggerated.” (after a quotation from mark twain). Acta Cytol. 2015;59(2):121–32.PubMedGoogle Scholar
  50. 50.
    Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, et al. The 2001 Bethesda system: terminology for reporting results of cervical cytology. JAMA. 2002;287(16):2114–9.PubMedGoogle Scholar
  51. 51.
    Centers for Disease Control and Prevention. 2015 sexually transmitted diseases treatment guidelines: HPV-associated cancers and precancers 2015. Available from: http://www.cdc.gov/std/tg2015/hpv-cancer.htm.
  52. 52.
    Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35(9):1127–34.PubMedGoogle Scholar
  53. 53.
    Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: a review. World J Gastrointest Surg. 2016;8(1):41–51.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Aberg JA, Gallant JE, Ghanem KG, Emmanuel P, Zingman BS, Horberg MA, et al. Primary care guidelines for the management of persons infected with HIV: 2013 update by the HIV medicine Association of the Infectious Diseases Society of America. Clin Infect Dis. 2014;58(1):1–10.PubMedGoogle Scholar
  55. 55.
    New York State Department of Health AIDS Institute. HIV clinical resource: anal dysplasia and cancer. New York: New York State Department of Health; 2007.Google Scholar
  56. 56.
    Xue R, Elbendary A, Valdebran M, Chaudhari S, Elston D. Pathologic features of anogenital precancerous high-grade squamous intraepithelial lesion (squamous cell carcinoma in situ). J Cutan Pathol. 2016;43(9):735–9.PubMedGoogle Scholar
  57. 57.
    Sahasrabuddhe VV, Luhn P, Wentzensen N. Human papillomavirus and cervical cancer: biomarkers for improved prevention efforts. Future Microbiol. 2011;6(9):1083–98.PubMedGoogle Scholar
  58. 58.
    Mao C, Balasubramanian A, Yu M, Kiviat N, Ridder R, Reichert A, et al. Evaluation of a new p16(INK4A) ELISA test and a high-risk HPV DNA test for cervical cancer screening: results from proof-of-concept study. Int J Cancer. 2007;120(11):2435–8.PubMedGoogle Scholar
  59. 59.
    Galgano MT, Castle PE, Atkins KA, Brix WK, Nassau SR, Stoler MH. Using biomarkers as objective standards in the diagnosis of cervical biopsies. Am J Surg Pathol. 2010;34(8):1077–87.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Bergeron C, Ordi J, Schmidt D, Trunk MJ, Keller T, Ridder R, et al. Conjunctive p16INK4a testing significantly increases accuracy in diagnosing high-grade cervical intraepithelial neoplasia. Am J Clin Pathol. 2010;133(3):395–406.PubMedGoogle Scholar
  61. 61.
    Petry KU, Schmidt D, Scherbring S, Luyten A, Reinecke-Luthge A, Bergeron C, et al. Triaging pap cytology negative, HPV positive cervical cancer screening results with p16/Ki-67 dual-stained cytology. Gynecol Oncol. 2011;121(3):505–9.PubMedGoogle Scholar
  62. 62.
    Schmidt D, Bergeron C, Denton KJ, Ridder R, European CCSG. p16/ki-67 dual-stain cytology in the triage of ASCUS and LSIL papanicolaou cytology: results from the European equivocal or mildly abnormal Papanicolaou cytology study. Cancer Cytopathol. 2011;119(3):158–66.PubMedGoogle Scholar
  63. 63.
    Wentzensen N, Follansbee S, Borgonovo S, Tokugawa D, Schwartz L, Lorey TS, et al. Human papillomavirus genotyping, human papillomavirus mRNA expression, and p16/Ki-67 cytology to detect anal cancer precursors in HIV-infected MSM. AIDS. 2012;26(17):2185–92.PubMedPubMedCentralGoogle Scholar
  64. 64.
    Alberts CJ, van Rooijen MS, Prins M, Pawlita M. Schim van der Loeff MF, Waterboer T. HIV is an important risk factor for human papillomavirus types 16 and 18 seropositivity among sexually active men who have sex with men. Sex Transm Dis. 2015;42(3):129–34.PubMedGoogle Scholar
  65. 65.
    Dupin C, Siproudhis L, Henno S, Minjolle S, Arvieux C, Tattevin P. Use of human papillomavirus genotyping and biomarkers for targeted screening of anal dysplasia in human immunodeficiency virus-infected patients. Dig Liver Dis. 2015;47(5):423–8.PubMedGoogle Scholar
  66. 66.
    Halloush RA, Akpolat I, Jim Zhai Q, Schwartz MR, Mody DR. Comparison of ProEx C with p16INK4a and Ki-67 immunohistochemical staining of cell blocks prepared from residual liquid-based cervicovaginal material: a pilot study. Cancer. 2008;114(6):474–80.PubMedGoogle Scholar
  67. 67.
    Larson BK, Mohanty SK, Wu JM, Bose S, Walts AE. ProEx C is a useful ancillary study for grading anal intraepithelial neoplasia alone and in combination with other biomarkers. APMIS. 2016;124(3):175–80.PubMedGoogle Scholar
  68. 68.
    Kocsis A, Takacs T, Jeney C, Schaff Z, Koiss R, Jaray B, et al. Performance of a new HPV and biomarker assay in the management of hrHPV positive women: subanalysis of the ongoing multicenter TRACE clinical trial (n > 6,000) to evaluate POU4F3 methylation as a potential biomarker of cervical precancer and cancer. Int J Cancer. 2017;140(5):1119–33.PubMedGoogle Scholar
  69. 69.
    Kolben TM, Kraft F, Kolben T, Goess C, Semmlinger A, Dannecker C, et al. Expression of Sialyl Lewis a, Sialyl Lewis x, Lewis y, Gal-3, Gal-7, STMN1 and p16 in cervical dysplasia. Future Oncol. 2017;13(2):145–57.PubMedGoogle Scholar
  70. 70.
    Park IU, Introcaso C, Dunne EF. Human papillomavirus and genital warts: a review of the evidence for the 2015 Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis. 2015;61(Suppl 8):S849–55.PubMedGoogle Scholar
  71. 71.
    Steben M, Garland SM. Genital warts. Best Pract Res Clin Obstet Gynaecol. 2014;28(7):1063–73.PubMedGoogle Scholar
  72. 72.
    Bellina JH. The use of the carbon dioxide laser in the management of condyloma acuminatum with eight-year follow-up. Am J Obstet Gynecol. 1983;147(4):375–8.PubMedGoogle Scholar
  73. 73.
    Wagenlehner FM, Brockmeyer NH, Discher T, Friese K, Wichelhaus TA. The presentation, diagnosis, and treatment of sexually transmitted infections. Dtsch Arztebl Int. 2016;113(1–02):11–22.PubMedPubMedCentralGoogle Scholar
  74. 74.
    Yanofsky VR, Patel RV, Goldenberg G. Genital warts: a comprehensive review. J Clin Aesthet Dermatol. 2012;5(6):25–36.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Massad LS, Einstein MH, Huh WK, Katki HA, Kinney WK, Schiffman M, et al. 2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Obstet Gynecol. 2013;121(4):829–46.PubMedGoogle Scholar
  76. 76.
    Weis SE. Current treatment options for management of anal intraepithelial neoplasia. Onco Targets Ther. 2013;6:651–65.PubMedPubMedCentralGoogle Scholar
  77. 77.
    NIH US National Library of Medicine. The Anchor Study. Available from: https://clinicaltrials.gov/ct2/show/NCT02135419.
  78. 78.
    Chabeda A, Yanez RJR, Lamprecht R, Meyers AE, Rybicki EP, Hitzeroth II. Therapeutic vaccines for high-risk HPV-associated diseases. Papillomavirus Res. 2017;5:46–58.PubMedPubMedCentralGoogle Scholar
  79. 79.
    Fortes HR, von Ranke FM, Escuissato DL, Araujo Neto CA, Zanetti G, Hochhegger B, et al. Recurrent respiratory papillomatosis: a state-of-the-art review. Respir Med. 2017;126:116–21.PubMedGoogle Scholar
  80. 80.
    Best SR, Mohr M, Zur KB. Systemic bevacizumab for recurrent respiratory papillomatosis: a national survey. Laryngoscope. 2017;127(10):2225–9.PubMedPubMedCentralGoogle Scholar
  81. 81.
    Sidell DR, Nassar M, Cotton RT, Zeitels SM, de Alarcon A. High-dose sublesional bevacizumab (avastin) for pediatric recurrent respiratory papillomatosis. Ann Otol Rhinol Laryngol. 2014;123(3):214–21.PubMedGoogle Scholar
  82. 82.
    Ahmed MM, Connor MP, Palazzolo M, Thompson ME, Lospinoso J, O’Connor P, et al. Effect of high-dose vocal fold injection of cidofovir and bevacizumab in a porcine model. Laryngoscope. 2017;127(3):671–5.PubMedGoogle Scholar
  83. 83.
    Murono S, Nakanishi Y, Tsuji A, Endo K, Kondo S, Wakisaka N, et al. Intralesional cidofovir injection for recurrent respiratory papillomatosis in Japan. Auris Nasus Larynx. 2016;43(5):541–5.PubMedGoogle Scholar
  84. 84.
    Bryan JT, Buckland B, Hammond J, Jansen KU. Prevention of cervical cancer: journey to develop the first human papillomavirus virus-like particle vaccine and the next generation vaccine. Curr Opin Chem Biol. 2016;32:34–47.PubMedGoogle Scholar
  85. 85.
    Cloessner EA, Stokley S, Yankey D, Markowitz LE. Timing of HPV vaccine intervals among United States teens with consideration to the current ACIP schedule and the WHO 2-dose schedule. Hum Vaccin Immunother. 2016;12(6):1375–80.PubMedGoogle Scholar
  86. 86.
    Basu P, Bhatla N, Ngoma T, Sankaranarayanan R. Less than 3 doses of the HPV vaccine – review of efficacy against virological and disease end points. Hum Vaccin Immunother. 2016;12(6):1394–402.PubMedPubMedCentralGoogle Scholar
  87. 87.
    World Health Organization. Evidence based recommendations on Human Papilloma Virus (HPV) Vaccines Schedules 2014. Available from: http://www.who.int/immunization/sage/meetings/2014/april/1_HPV_Evidence_based_recommendationsWHO_with_Appendices2_3.pdf.
  88. 88.
    Laprise JF, Markowitz LE, Chesson HW, Drolet M, Brisson M. Comparison of 2-dose and 3-dose 9-valent human papillomavirus vaccine schedules in the United States: a cost-effectiveness analysis. J Infect Dis. 2016;214(5):685–8.PubMedPubMedCentralGoogle Scholar
  89. 89.
    Petrosky E, Bocchini JA Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, et al. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortal Wkly Rep. 2015;64(11):300–4.PubMedPubMedCentralGoogle Scholar
  90. 90.
    Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–65.PubMedGoogle Scholar
  91. 91.
    Naud PS, Roteli-Martins CM, De Carvalho NS, Teixeira JC, de Borba PC, Sanchez N, et al. Sustained efficacy, immunogenicity, and safety of the HPV-16/18 AS04-adjuvanted vaccine: final analysis of a long-term follow-up study up to 9.4 years post-vaccination. Hum Vaccin Immunother. 2014;10(8):2147–62.PubMedPubMedCentralGoogle Scholar
  92. 92.
    Walker TY, Elam-Evans LD, Singleton JA, Yankey D, Markowitz LE, Fredua B, et al. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years – United States, 2018. MMWR Morb Mortal Wkly Rep. 2019;68(33):718–23.Google Scholar
  93. 93.
    World Health Organization. Human papillomavirus (HPV) and cervical cancer Fact Sheet 2016. Available from: http://www.who.int/entity/mediacentre/factsheets/fs380/en/.
  94. 94.
    Drolet M, Benard E, Boily MC, Ali H, Baandrup L, Bauer H, et al. Population-level impact and herd effects following human papillomavirus vaccination programmes: a systematic review and meta-analysis. Lancet Infect Dis. 2015;15(5):565–80.PubMedPubMedCentralGoogle Scholar
  95. 95.
    Novakovic D, Cheng ATL, Zurynski Y, Booy R, Walker PJ, Berkowitz R, et al. A prospective study of the incidence of juvenile-onset recurrent respiratory papillomatosis after implementation of a national HPV vaccination program. J Infect Dis. 2018;217(2):208–12.PubMedGoogle Scholar
  96. 96.
    Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, et al. Human papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(RR-05):1–30.PubMedGoogle Scholar
  97. 97.
    Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and US safety monitoring plans for nine-valent HPV vaccine. Hum Vaccin Immunother. 2016;12:1406–17.PubMedPubMedCentralGoogle Scholar
  98. 98.
    Garland SM, Ault KA, Gall SA, Paavonen J, Sings HL, Ciprero KL, et al. Pregnancy and infant outcomes in the clinical trials of a human papillomavirus type 6/11/16/18 vaccine: a combined analysis of five randomized controlled trials. Obstet Gynecol. 2009;114(6):1179–88.PubMedGoogle Scholar
  99. 99.
    Choudhury SA, Choudhury NA, Humphrey AD, Berthaud V, Ladson G, Tucker VA, et al. Higher prevalence of human papillomavirus-related cervical precancerous abnormalities in HIV-infected compared to HIV-uninfected women. J Natl Med Assoc. 2016;108(1):19–23.PubMedGoogle Scholar
  100. 100.
    Faust H, Toft L, Sehr P, Muller M, Bonde J, Forslund O, et al. Human papillomavirus neutralizing and cross-reactive antibodies induced in HIV-positive subjects after vaccination with quadrivalent and bivalent HPV vaccines. Vaccine. 2016;34(13):1559–65.PubMedGoogle Scholar
  101. 101.
    Kojic EM, Rana AI, Cu-Uvin S. Human papillomavirus vaccination in HIV-infected women: need for increased coverage. Expert Rev Vaccines. 2016;15(1):105–17.PubMedGoogle Scholar
  102. 102.
    Nielson CM, Flores R, Harris RB, Abrahamsen M, Papenfuss MR, Dunne EF, et al. Human papillomavirus prevalence and type distribution in male anogenital sites and semen. Cancer Epidemiol Biomarkers Prev. 2007;16(6):1107–14.PubMedGoogle Scholar
  103. 103.
    Chin-Hong PV, Vittinghoff E, Cranston RD, Buchbinder S, Cohen D, Colfax G, et al. Age-specific prevalence of anal human papillomavirus infection in HIV-negative sexually active men who have sex with men: the EXPLORE study. J Infect Dis. 2004;190(12):2070–6.PubMedGoogle Scholar
  104. 104.
    Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis. 1998;177(2):361–7.PubMedGoogle Scholar
  105. 105.
    Chin-Hong PV, Palefsky JM. Human papillomavirus anogenital disease in HIV-infected individuals. Dermatol Ther. 2005;18(1):67–76.PubMedGoogle Scholar
  106. 106.
    Mendez-Martinez R, Rivera-Martinez NE, Crabtree-Ramirez B, Sierra-Madero JG, Caro-Vega Y, Galvan SC, et al. Multiple human papillomavirus infections are highly prevalent in the anal canal of human immunodeficiency virus-positive men who have sex with men. BMC Infect Dis. 2014;14:671.PubMedPubMedCentralGoogle Scholar
  107. 107.
    Piketty C, Darragh TM, Da Costa M, Bruneval P, Heard I, Kazatchkine MD, et al. High prevalence of anal human papillomavirus infection and anal cancer precursors among HIV-infected persons in the absence of anal intercourse. Ann Intern Med. 2003;138(6):453–9.PubMedGoogle Scholar
  108. 108.
    Piketty C, Darragh TM, Heard I, Da Costa M, Bruneval P, Kazatchkine MD, et al. High prevalence of anal squamous intraepithelial lesions in HIV-positive men despite the use of highly active antiretroviral therapy. Sex Transm Dis. 2004;31(2):96–9.PubMedGoogle Scholar
  109. 109.
    Eaton L, Kalichman S, Cain D, Cherry C, Pope H, Fuhrel A, et al. Perceived prevalence and risks for human papillomavirus (HPV) infection among women who have sex with women. J Womens Health (Larchmt). 2008;17(1):75–83.Google Scholar
  110. 110.
    McNair R, Power J, Carr S. Comparing knowledge and perceived risk related to the human papilloma virus among Australian women of diverse sexual orientations. Aust N Z J Public Health. 2009;33(1):87–93.PubMedGoogle Scholar
  111. 111.
    Pelullo CP, Di Giuseppe G, Angelillo IF. Human papillomavirus infection: knowledge, attitudes, and behaviors among lesbian, gay men, and bisexual in Italy. PLoS One. 2012;7(8):e42856.PubMedPubMedCentralGoogle Scholar
  112. 112.
    Reiter PL, McRee AL. HPV infection among a population-based sample of sexual minority women from USA. Sex Transm Infect. 2017;93(1):25–31.PubMedGoogle Scholar
  113. 113.
    Machalek DA, Poynten M, Jin F, Fairley CK, Farnsworth A, Garland SM, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol. 2012;13(5):487–500.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Duke University School of MedicineDurhamUSA
  2. 2.Emory University School of MedicineAtlantaUSA

Personalised recommendations